Abu Dhabi Sleep Apnea (ADSA) Study

Imperial College London Diabetes Centre

Status: Unknown

Conditions: Sleep Apnoea

Treatments: Other: Questionnaire

Study type: Observational

Funder types: Other

Identifiers

NCT02403141

IREC020

Details and patient eligibility

About

Obstructive sleep apnoea (OSA) is a common medical problem which, despite increasing awareness, remains under-diagnosed. There is a close association between OSA and obesity; 60-70% of patients diagnosed with OSA are either obese or overweight [1]. OSA is also very common among patients with type 2 diabetes. Type 2 Diabetes Mellitus (T2DM) has reached epidemic status in the Gulf region. OSA worsens insulin resistance and leads to weight gain through sleep disturbance [2]. Several mechanisms have been proposed for the associations of OSA with diabetes and obesity [3]. At present there is little available information regarding the prevalence of OSA in the UAE, the relationship with T2DM and obesity, and the impact of OSA on health outcomes in the Emirati population. This research will explore these relationships and inform public health decisions regarding diagnostic pathways, service provision and treatment protocols.

Enrollment: 1,400 estimated patients

Sex: All

Ages: 18 to 64 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

Participants aged between 18-64 years old. Both Gender male and female.

Exclusion criteria

Paediatrics below the age of 18. Any participant who is unable to take part

Trial design

1,400 participants in 4 patient groups

Normal glucose tolerance

Description:

Patients with normal fasting glucose. Blood glucose less than 5.6mmol/L

Treatment:

Other: Questionnaire

Impaired fasting glycaemia

Description:

Patients with blood glucose between 5.6mmol/L - 7mmol/L

Treatment:

Other: Questionnaire

Type 2 diabetes

Description:

Patients with blood glucose higher than 7mmol/L and negative IA2 and GAD antibodies.

Treatment:

Other: Questionnaire

Type 1 diabetes

Description:

Patients on insulin and with positive IA2 and/or GAD antibodies.

Treatment:

Other: Questionnaire